Perceptive Inc. is attending EFMC Medicinal Chemistry 2026 in Basel, Switzerland, where Dr. Christophe Plisson will present work on the radiosynthesis, preclinical assessment, and clinical translation of the novel DAAO PET ligand [¹⁸F]PGM028299 (LE036).
Public source
Publisher name
Public post
Join us at EFMC Medicinal Chemistry 2026 in Basel, Switzerland! Dr. Christophe Plisson, Head of Preclinical Services at Perceptive Discovery, will present our work on th…
Company
Perceptive Inc.
Delivering Discovery, eClinical, and Imaging Solutions to the Global Biopharmaceutical Industry
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 1,001–5,000 employees
About Perceptive Inc.
Expanding on their combined 50-year history, Perceptive provides best-in-class specialist support to global pharmaceutical, biotech, and clinical research organizations, spanning the complete R&D lifecycle, from discovery and preclinical through clinical development to post marketing. Perceptive’s offerings include imaging biomarkers and core lab services, as well as innovative technologies in randomization and trial supply management (RTSM), analytics, and software.
See moreLatest activity
Latest activity from Perceptive Inc.
19 signals
Research & Knowledge
Perceptive Inc. published an analysis examining site-central discordance across a large dataset of solid tumor clinical trials led by Greg Goldmacher, MD, PhD, now Chief Scientific & Medical Officer.
Research & Knowledge
Perceptive Inc. published a paper titled Site/central discordance in oncology trials on site/central discordance in oncology trials.
Presence & Recognition
Perceptive Inc. is hosting a webinar featuring Julian Goggi, PhD, to explore the science behind RLT combination strategies and translational tools for evaluating them.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Nuvisan
Nuvisan is exhibiting at the EFMC 2026 event in Basel at Booth 14 to discuss medicinal chemistry, custom synthesis, lead optimisation, microbiological chemistry, direct-to-biology, route scouting, process development, and scale-up.
Presence & Recognition
Domainex
Domainex is exhibiting at booth #2 at the EFMC European Federation for Medicinal Chemistry and Chemical Biology event to discuss integrated drug discovery projects.
Presence & Recognition
IRBM
IRBM is attending the EFMC International Symposium on Medicinal Chemistry in Basel, France, from September 8 to September 11, 2026.
Presence & Recognition
Novalix
Novalix is exhibiting at the EFMC 2026 conference in Basel, Switzerland, booth No. 30, presenting an oral communication on Discovery of Novel METTL3 Inhibitors for the Treatment of Cancer and a workshop on From Bench to Automation.
Presence & Recognition
Eurofins Discovery